Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10012313 | 0.94 | TSHR (0.39) | TSHRSLC1A2MEN1KMT2ACHRNB2 | |
| SCHEMBL10012641 | 0.93 | TSHR (0.33) | TSHRSLC1A2MEN1KMT2ACHRNB2 | |
| SCHEMBL10011415 | 0.89 | TSHR (0.40) | TSHRSLC1A2MEN1KMT2ACHRNB2 | |
| SCHEMBL10011875 | 0.87 | TSHR (0.34) | TSHRSLC1A2MEN1KMT2ACHRNB2 | |
| SCHEMBL10012603 | 0.85 | TSHR (0.33) | TSHRMEN1KMT2A | |
| SCHEMBL19881228 | 0.84 | NAAA (0.36) | TSHRMEN1KMT2A | |
| SCHEMBL21137683 | 0.82 | MEN1 (0.36) | TSHRMEN1KMT2A | |
| SCHEMBL14353237 | 0.81 | KMT2A (0.47) | TSHRSLC1A2MEN1KMT2A | |
| SCHEMBL12430278 | 0.79 | TSHR (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL10012054 | 0.79 | TSHR (0.34) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9130244-B2 | Nonaqueous electrolyte solution and electrochemical element using same | UBE INDUSTRIES, LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| EP-2908376-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2479831-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | Ube Industries, Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171581-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | SLC8A1, OR10J3, SLC8B1 | TSHR 3669/4885SLC1A2 195/4885MEN1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.